PRMA Consulting HTA Manager Claire Chadwick in a recent blog post discusses five common omissions in global value dossiers. Chadwick says the following five omissions lead to less robust dossiers: Inadequate justification Insufficient trial and analysis information Poor consideration […]
Value & Outcomes Spotlight Editor-in-Chief Bids Farewell in Latest Issue
Value & Outcomes Spotlight Editor-in-Chief David Thompson bid readers farewell in the latest issue, describing his 12-plus years in the position as "extremely gratifying." "I also look forward to connecting with friends and colleagues throughout the ISPOR community as circumstances permit us […]
Report: Responses to Remdesivir Price Mostly Negative
Even though the Institute for Clinical for Economic Review (ICER) announced its support of remdesivir's pricing, the response has been mostly negative, FiercePharma reports. West Health Policy Center Health Policy Director Sean Dickson said the pricing announcement confirmed a majority of […]
Healthcare Reimbursement Market to Reach $20 billion by 2025, Report Suggests
The U.S. healthcare reimbursement market could be valued at $20 billion by 2025, according to a new report by Brand Essence Market Research. "Growing level of costs associated with the healthcare services and products, increasing prevalence and organizing of government-led healthcare programs are […]
Report: FDA Mandates 50% Efficacy for COVID-19 Vaccines
Vaccine candidates must be at least 50 percent more effective than a placebo to be considered for Food and Drug Administration approval, according to a FiercePharma report. However, some experts have expressed concerns about that guidance, according to the report, with some suggesting that level […]
Pandemic Puts Pressure on FDA on RWD
The COVID-19 pandemic has put increased pressure on the Food and Drug Administration's real-world data initiatives. According to a Pink Sheet report, the agency is set to hear from stakeholders on its data plans. To read the report, click here.(Paid subscription required) […]
Mental Care Utilization Poised to be Key Driver of Health Spending Next Year
PwC in a new analysis suggests utilization of mental care services will be a key driver of health spending next year, HealthPayerIntelligence reports. The analysis also found, however, that increased use of telehealth services could offer some balance to rising prices. "In 2021, HRI expects […]
Report on PBM Market Forecasts 7% CAGR Between 2019-2025
A new report from Arizton forecasts a compound annual growth rate of 7 percent for the pharmacy benefit management market between 2019-2025. The report spotlights a number of companies, including Abarca Health, BeneCard PBF, CVS Caremark and Express Scripts. "With a high number of consumers […]
Webinar to Highlight Marketplace Trends, COVID-19’s Impact
The Academy of Managed Care Pharmacy (AMCP) is set to host a July 9 webinar on trends in the health care industry since COVID-19. Slated to begin 2 p.m. EST, the webinar will feature IQVIA's Douglas Long. AMCP CEO Susan Cantrell will moderate the event. "The COVID-19 global pandemic has had a […]
Reminder: ICER Accepting Comments on Annual Unsupported Price Increase Assessment
The Institute for Clinical and Economic Review (ICER) is accepting public input on the target drugs for this year's Unsupported Price Increase Assessment. Public feedback will be accepted until July 17. According to ICER, the final report is slated to be posted on Jan. 8, 2021. To read the […]
PhRMA Foundation Extends Deadline on Applications for Value Assessment Awards
The PhRMA Foundation announced an extended application deadline for the foundation's 2020 Value Assessment Awards. Applications are due July 15. The foundation is accepting applications for the Value Assessment Challenge Awards and Value Assessment Research Awards. To learn more, click here. […]
Gilead Sets Price for Remdesivir
Gilead announced it would charge between $2,340 and $3,120 for a 5-day course of its COVID-19 drug remdesivir, BioPharma Dive reports. According to the report, Gilead plans to offer the drug to the governments in developed countries with a price tag of $390 per vial. Private entities and some […]
DistillerSR Week 2020 Recap Reel
The Evidence Partners posted a quick highlight reel of DistillerSR Week 2020, its first-ever virtual user conference. Click here to watch the highlight reel. […]
PRMA’s Nathan White: Why Understanding Payer Archetypes is Key to U.S. Market Access
Via PRMA Consulting Until recently, pharma’s biggest market access challenge in the U.S. has been learning to navigate "known unknowns." Suddenly, however, long-standing unknowns – like the future of the Affordable Care Act, the nature of pricing reforms, or the influence of the Institute for […]
Pricing a COVID-19 Vaccine
A recent episode of NPR's INDICATOR offers a look at the issue of pricing a vaccine for COVID-19. The episode featured Michael Kinch, who heads the Centers for Research Innovation in Biotechnology and Drug Development. Kinch said the price of a COVID-19 vaccine might prove "surprising" to some […]
How is COVID-19 Impacting RWD-Based Initiatives in Oncology?
A recent OncLive article looks at how the COVID-19 pandemic is shaping real-world data initiatives in the oncology landscape. The Food and Drug Administration (FDA) is in the process of modifying how RWD is used in cancer care, according to the article. "We now find ourselves in a grand […]
Proposed Medicaid Changes Aim to Foster Innovative Contracts
The Centers for Medicare and Medicaid Services (CMS) is hoping to encourage greater use of innovative contracting models in a recently-proposed package of changes to Medicaid. Washington University in St. Louis associate law professor Rachel Sachs in a recent Health Affairs blog post writes that […]
IQVIA Offering On-Demand Webinar on RWE
IQVIA is offering on-demand access to its recent web event on real-world evidence. The webinar was hosted in partnership with Pharmaceutical Executive on June 25. For more information, click here. […]
CSRxP’s Aronson: Pharma Must Halt Summer Price Hikes
The Campaign for Sustainable Rx Pricing (CSRxP) is calling on the pharmaceutical industry to halt summer price hikes as the country grapples with the COVID-19 pandemic. In an opinion piece published on Morning Consult, CSRxP Executive Director Lauren Aronson writes "patients and families need […]
Article Highlights Causes, Potential Solutions for High Drug Prices
While there are "no easy solutions" to high drug prices, there are a number of steps that could help wrangle prices, according to a recent article published in Nature. The author, S. Vincent Rajkumar, writes that global prescription drug spending is set to hit roughly $1.3 trillion this year, […]
ISPOR Plans Educational Webinar for Members
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is set to host a webinar aimed at helping members bolster their leadership skills. The webinar, "Pathways to ISPOR Leadership," is set for 10 a.m. EST July 14. To learn more, click here. […]
ICER to Assess Roxadustat for Treatment Anemia in Chronic Kidney Disease
The Institute for Clinical and Economic Review (ICER) announced plans to assess FibroGen's roxadustat for the treatment of anemia in chronic kidney disease. An open input period will remain open until 5 p.m. EST July 15. According to a press release, a document outlining the planned review […]
PBMs Report Ease in Demand for Hydroxychloroquine
Pharmacy benefit managers last month reported an easing of demand for the antimalarial drug hydroxychloroquine following a rapid surge spurred by comments by the White House, Specialty Pharmacy Continuum reports. The Trump administration had in the past suggested the drug was an effective […]
Valid Insight Report Explores Insights from Roundtable on Payer Engagement
A new report from Valid Insight explores key insights generated from a roundtable discussion on payer engagement. The white paper, "Excellence in Payer Engagement: Strategic Outputs From A Roundtable Discussion," includes input from a number of stakeholders in the pharmaceutical […]
Podcast Highlights ‘Buy and Bill’ Model in Oncology
Memorial Sloan Kettering Cancer Center's Dr. Aaron Mitchell in the latest Relentless Health Value podcast discusses the "buy and bill" payment model in oncology. Mitchell is an oncologist and health services researcher. The podcast explores how hospitals are reimbursed for infusing high-cost […]
OptumRx: Rising Orphan Drug Competition Could Lead to Lower Prices
Increased competition in the orphan drug market could ultimately help pull down prices, OptumRx suggests in a new report. According to the report, roughly 40 percent of drugs approved this year will be orphan drugs. "What is new is that we now are starting to see the development of orphan […]
ACR Tapped as Imaging Partner for COVID-19 Registry
The Society of Clinical Care Medicine (SCCM) has chosen the American College of Radiology (ACR) to be the main imaging repository for a COVID-19 registry. The Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS) registry is part of an initiative aimed at developing a […]
Report: HEOR Services Market Poised for Rapid Growth
The health economics and outcomes research (HEOR) services market is set to see "rapid growth" between 2020-2025, according to a new report by Reports Intellect. The report profiles a number of companies, including Axtria, Avalon Health Economics, ICON, McKesson, PAREXEL and Syneos Health. To […]
Legislation Aims to Prevent Pharma From Price-gouging During Pandemic
Two new bipartisan bills introduced by House Democrats aim to prevent the pharmaceutical industry from engaging in price-gouging on COVID-19 treatments, according to a Common Dreams report. The legislation was introduced following a recent poll that found a whopping 88 percent of Americans fear […]
Report Reveals Racial Disparities in COVID-19 Outcomes
New data released by the government on Monday suggests black Americans under Medicare were roughly four times more likely as white Americans to be hospitalized for COVID-19, Reuters reports. The data was released by the Centers for Medicare and Medicaid Services. "The disparities in the data […]
